Drugs

, Volume 71, Issue 13, pp 1675–1688

Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus

Current and Emerging Agents
  • Baptist Gallwitz
Review Article

Abstract

Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 receptor agonists acting on the GLP-1 receptor, exenatide and liraglutide are available in many countries. In type 2 diabetes treatment, incretin-based therapies are attractive and more commonly used because of their mechanism of action and safety profile. Stimulation of insulin secretion and inhibition of glucagon secretion by these agents occur in a glucose-dependent manner. Therefore, incretin-based therapies have no intrinsic risk for hypoglycaemia. Furthermore, GLP-1 receptor agonists allow weight loss and lower systolic blood pressure. This review gives a brief overview of the mechanism of action and summarizes the clinical data available on exenatide and liraglutide as established substances. It further highlights the clinical study data of exenatide once weekly as the first long-acting GLP-1 receptor agonist and covers other new long acting GLP-1 receptor agonists currently in clinical development. The placement of GLP-1 receptor agonists in the treatment algorithm of type 2 diabetes is discussed.

References

  1. 1.
    International Diabetes Federation (IDF). Diabetes atlas 2009 [online]. Available from URL: http://www.diabetesatlas.org [Accessed 2011 Jul 13]
  2. 2.
    Zeitler P. Update on nonautoimmune diabetes in children. J Clin Endocrinol Metab 2009; 94: 2215–20PubMedCrossRefGoogle Scholar
  3. 3.
    Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93PubMedCrossRefGoogle Scholar
  4. 4.
    Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–91PubMedCrossRefGoogle Scholar
  5. 5.
    Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89PubMedCrossRefGoogle Scholar
  6. 6.
    Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711–21Google Scholar
  7. 7.
    Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102–10PubMedCrossRefGoogle Scholar
  8. 8.
    Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802–12PubMedCrossRefGoogle Scholar
  9. 9.
    Wellendorph P, Johansen LD, Brauner-Osborne H. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol Pharmacol 2009; 76: 453–65PubMedCrossRefGoogle Scholar
  10. 10.
    Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75–85PubMedCrossRefGoogle Scholar
  11. 11.
    Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46–52PubMedCrossRefGoogle Scholar
  12. 12.
    Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301–7PubMedCrossRefGoogle Scholar
  13. 13.
    Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741–4PubMedCrossRefGoogle Scholar
  14. 14.
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–705PubMedCrossRefGoogle Scholar
  15. 15.
    Gallwitz B, Witt M, Folsch UR, et al. Binding specificity and signal transduction of receptors for glucagon-like peptide-1 (7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. J Mol Endocrinol 1993; 10: 259–68PubMedCrossRefGoogle Scholar
  16. 16.
    Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69–72PubMedCrossRefGoogle Scholar
  17. 17.
    Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7–14PubMedCrossRefGoogle Scholar
  18. 18.
    Porter DW, Kerr BD, Flatt PR, et al. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab 2010; 12: 891–9PubMedCrossRefGoogle Scholar
  19. 19.
    Brubaker PL, Drucker DJ. Mini review: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145: 2653–9PubMedCrossRefGoogle Scholar
  20. 20.
    Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130: 159–66PubMedCrossRefGoogle Scholar
  21. 21.
    Courreges JP, Vilsboll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25: 1129–31PubMedCrossRefGoogle Scholar
  22. 22.
    Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275–86PubMedGoogle Scholar
  23. 23.
    Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694–9PubMedCrossRefGoogle Scholar
  24. 24.
    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131–57PubMedCrossRefGoogle Scholar
  25. 25.
    Madsbad S, Kielgast U, Asmar M, et al. An overview of once-weekly GLP-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. Epub 2011 Jan 5Google Scholar
  26. 26.
    Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402–5Google Scholar
  27. 27.
    Raufman JP, Singh L, Singh G, et al. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 1992; 267: 21432–7Google Scholar
  28. 28.
    Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006; 60: 1654–61PubMedCrossRefGoogle Scholar
  29. 29.
    Gedulin BR, Smith P, Prickett KS, et al. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 2005; 48: 1380–5PubMedCrossRefGoogle Scholar
  30. 30.
    Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487–93PubMedCrossRefGoogle Scholar
  31. 31.
    Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195–202PubMedCrossRefGoogle Scholar
  32. 32.
    Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003; 52: 1786–91PubMedCrossRefGoogle Scholar
  33. 33.
    McGill JB. Insights from the Liraglutide Clinical Development Program-the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med 2009; 121: 16–25PubMedCrossRefGoogle Scholar
  34. 34.
    Werner U. Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010. Ann Endocrinol 2008; 69: 164–5CrossRefGoogle Scholar
  35. 35.
    Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009; 32: 1880–6PubMedCrossRefGoogle Scholar
  36. 36.
    Nauck MA, Ratner RE, Kapitza C, et al. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009; 32: 1237–43PubMedCrossRefGoogle Scholar
  37. 37.
    Retterstol K. Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. Expert Opin Investig Drugs 2009; 18: 1405–11PubMedCrossRefGoogle Scholar
  38. 38.
    Roche. Investor update: Roche announces amendment of the trial protocols for the taspoglutide phase III programme [online]. http://www.roche.com/investors/ir_update/inv-update-2010-06-18b.htm [Accessed 2011 Jun 22]
  39. 39.
    Barnett AH. Exenatide. Drugs Today 2005; 41: 563–78PubMedCrossRefGoogle Scholar
  40. 40.
    Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173–81PubMedGoogle Scholar
  41. 41.
    Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628–35PubMedCrossRefGoogle Scholar
  42. 42.
    DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–100CrossRefGoogle Scholar
  43. 43.
    Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083–91PubMedCrossRefGoogle Scholar
  44. 44.
    Barnett A. Exenatide. Expert Opin Pharmacother 2007; 8: 2593–608PubMedCrossRefGoogle Scholar
  45. 45.
    Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559–69PubMedGoogle Scholar
  46. 46.
    Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259–67PubMedCrossRefGoogle Scholar
  47. 47.
    Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477–85PubMedGoogle Scholar
  48. 48.
    Gallwitz B. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. Drug Saf 2010; 33: 87–100PubMedCrossRefGoogle Scholar
  49. 49.
    Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991–7PubMedCrossRefGoogle Scholar
  50. 50.
    Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762–8PubMedCrossRefGoogle Scholar
  51. 51.
    Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154(2): 103–12PubMedGoogle Scholar
  52. 52.
    Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240–50PubMedCrossRefGoogle Scholar
  53. 53.
    Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 2008; 358: 1970–1PubMedGoogle Scholar
  54. 54.
    Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med 2008; 358: 1969–70PubMedCrossRefGoogle Scholar
  55. 55.
    Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019–27PubMedCrossRefGoogle Scholar
  56. 56.
    Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010; 64: 984–90PubMedCrossRefGoogle Scholar
  57. 57.
    Yoo BK, Triller DM, Yoo DJ. Exenatide: a new option for the treatment of type 2 diabetes. Ann Pharmacother 2006; 40: 1777–84PubMedCrossRefGoogle Scholar
  58. 58.
    Food and Drug Administration (FDA). Medwatch alert: Byetta (exenatide)-Renal Failure, 2009 Nov 2 [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm [Accessed 2011 Jul 13]
  59. 59.
    Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol 2010; 25: 1207–17PubMedCrossRefGoogle Scholar
  60. 60.
    Malloy J, Capparelli E, Gottschalk M, et al. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Clin Ther 2009; 31: 806–15PubMedCrossRefGoogle Scholar
  61. 61.
    Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003; 140: 123–32PubMedCrossRefGoogle Scholar
  62. 62.
    Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473–81PubMedCrossRefGoogle Scholar
  63. 63.
    Garber AJ, Spann SJ. An overview of incretin clinical trials. J Fam Pract 2008; 57: S10–8PubMedGoogle Scholar
  64. 64.
    Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268–78PubMedCrossRefGoogle Scholar
  65. 65.
    Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med 2009; 121: 5–15PubMedCrossRefGoogle Scholar
  66. 66.
    Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84–90PubMedCrossRefGoogle Scholar
  67. 67.
    Nauck MA. Incretin hormones and their therapeutic potential in patients with type 2 diabetes [preface]. Best Pract Res Clin Endocrinol Metab 2009; 23: viiPubMedCrossRefGoogle Scholar
  68. 68.
    Nauck MA, Vilsboll T, Gallwitz B, et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32 Suppl. 2: S223–31PubMedCrossRefGoogle Scholar
  69. 69.
    Zinman B. The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies. Diabetes Obes Metab 2009; 11 Suppl. 3: 1–3PubMedCrossRefGoogle Scholar
  70. 70.
    Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 d2iabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224–30PubMedCrossRefGoogle Scholar
  71. 71.
    Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47PubMedCrossRefGoogle Scholar
  72. 72.
    Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 2009; 5: 199–211PubMedCrossRefGoogle Scholar
  73. 73.
    Vilsboll T. Liraglutide: a new treatment for type 2 diabetes. Drugs Today 2009; 45: 101–13PubMedGoogle Scholar
  74. 74.
    Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33: 1300–3PubMedCrossRefGoogle Scholar
  75. 75.
    Vilsboll T, Knop FK. Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus. Biodrugs 2008; 22: 251–7PubMedCrossRefGoogle Scholar
  76. 76.
    Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 152–6PubMedCrossRefGoogle Scholar
  77. 77.
    Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447–56PubMedCrossRefGoogle Scholar
  78. 78.
    Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008; 168: 1699–704PubMedCrossRefGoogle Scholar
  79. 79.
    Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59PubMedCrossRefGoogle Scholar
  80. 80.
    Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203PubMedCrossRefGoogle Scholar
  81. 81.
    Matthaei S, Bierwirth R, Fritsche A, et al. Medical anti-hyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 2009; 117: 522–57PubMedCrossRefGoogle Scholar
  82. 82.
    Ban K, Hui S, Drucker DJ, et al. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 2009; 3: 245–59PubMedCrossRefGoogle Scholar
  83. 83.
    Mussig K, Oncu A, Lindauer P, et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008; 102: 646–7PubMedCrossRefGoogle Scholar
  84. 84.
    Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962–5PubMedCrossRefGoogle Scholar
  85. 85.
    Eldridge JH, Staas JK, Tice TR, et al. Biodegradable poly(DL-lactide-co-glycolide) microspheres. Res Immunol 1992; 143: 557–63PubMedCrossRefGoogle Scholar
  86. 86.
    Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431–9PubMedCrossRefGoogle Scholar
  87. 87.
    Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33: 1255–61PubMedCrossRefGoogle Scholar
  88. 88.
    Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234–43PubMedCrossRefGoogle Scholar
  89. 89.
    Meier JJ, Gallwitz B, Schmidt WE, et al. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002; 440: 269–79PubMedCrossRefGoogle Scholar
  90. 90.
    Wang GJ, Tomasi D, Backus W, et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage 2008; 39: 1824–31PubMedCrossRefGoogle Scholar
  91. 91.
    Amylin Pharmaceuticals, Inc. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT01144338]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Aug 15]
  92. 92.
    Best JH, Boye KS, Rubin RR, et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009; 26: 722–8PubMedCrossRefGoogle Scholar
  93. 93.
    Bush MA, Matthews JE, De Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009; 11: 498–505PubMedCrossRefGoogle Scholar
  94. 94.
    Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009; 25: 3049–57PubMedCrossRefGoogle Scholar
  95. 95.
    Nauck MA, Kemmeries G, Holst JJ, et al. Rapid tachyphylaxis of the glucagon-like peptide-1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60(5): 1561–5PubMedCrossRefGoogle Scholar
  96. 96.
    Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149–58PubMedCrossRefGoogle Scholar
  97. 97.
    Waldron-Lynch F, von Herrath M, Herold KC. Towards a curative therapy in type 1 diabetes: remission of auto-immunity, maintenance and augmentation of beta cell mass. Novartis Found Symp 2008; 292: 146–55PubMedCrossRefGoogle Scholar
  98. 98.
    Raman VS, Heptulla RA. New potential adjuncts to treatment of children with type 1 diabetes mellitus. Pediatr Res 2009; 65: 370–4PubMedCrossRefGoogle Scholar
  99. 99.
    Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7–36) amide in type I diabetic patients. Diabetes Care 1996; 19: 580–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Baptist Gallwitz
    • 1
  1. 1.Medizinische Klinik IVEberhard-Karls UniversityTübingenGermany

Personalised recommendations